Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Chloe Thornton, GlobalData's company analyst, also recently observed that GSK has major problems with a lack ... The biggest vaccine brand it has acquired in the deal is Bexsero, a new vaccine ...

The four-pronged strategy begins with the acquisition of GSK's oncology portfolio ... health division to Lilly for $5.4 billion reflects major changes in the animal health market, sparked by ...

While generics may dominate due to cost advantages and meeting needs of a developing economy, there is a growing thrust ...

GSK cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations ...

It would be unhealthy to let Robert F. Kennedy Jr. take charge of U.S. physical well-being. President-elect Donald Trump said on the campaign trail that he wants the anti-vaccine activist to “run wild ...

The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to ... planning launches for five major new product approval opportunities next ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

"mRNA licensing agreements surge 800% amid GSK lawsuits" was originally created and published by Pharmaceutical Technology, a ...

GSK's vaccine sales, including RSV and Shingrix, decline amid changing US recommendations, impacting Q3 performance and ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...